Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Profit After Tax (2020 - 2025)

Rani Therapeutics Holdings has reported Profit After Tax over the past 6 years, most recently at -$21.6 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$21.6 million for Q4 2025, down 299.02% from a year ago — trailing twelve months through Dec 2025 was -$51.0 million (down 111.62% YoY), and the annual figure for FY2025 was -$40.9 million, down 36.42%.
  • Profit After Tax for Q4 2025 was -$21.6 million at Rani Therapeutics Holdings, down from -$5.4 million in the prior quarter.
  • Over the last five years, Profit After Tax for RANI hit a ceiling of $10.8 million in Q4 2024 and a floor of -$49.9 million in Q4 2021.
  • Median Profit After Tax over the past 5 years was -$14.3 million (2022), compared with a mean of -$15.7 million.
  • Biggest five-year swings in Profit After Tax: crashed 895.49% in 2021 and later surged 126.44% in 2024.
  • Rani Therapeutics Holdings' Profit After Tax stood at -$49.9 million in 2021, then surged by 65.28% to -$17.3 million in 2022, then crashed by 136.48% to -$41.0 million in 2023, then surged by 126.44% to $10.8 million in 2024, then tumbled by 299.02% to -$21.6 million in 2025.
  • The last three reported values for Profit After Tax were -$21.6 million (Q4 2025), -$5.4 million (Q3 2025), and -$11.2 million (Q2 2025) per Business Quant data.